Literature DB >> 17994214

Relationship between lipid profiles and kidney function in patients with type 1 diabetes.

N Tolonen1, C Forsblom, L Thorn, J Wadén, M Rosengård-Bärlund, M Saraheimo, O Heikkilä, K Pettersson-Fernholm, M-R Taskinen, P-H Groop.   

Abstract

AIMS/HYPOTHESIS: We studied the relationship between the lipid profile, estimated GFR (eGFR) and AER in patients with type 1 diabetes. We also assessed the association between the lipid profile and glycaemic control, obesity and hypertension in an environment free of manifest renal disease, as well as exploring how well the patients would have achieved the targets set in international guidelines.
METHODS: A total of 2,927 adult patients who had type 1 diabetes and for whom lipid profiles were available were included from people participating in the nationwide, multicentre Finnish Diabetic Nephropathy Study (FinnDiane). eGFR was determined using the Cockcroft-Gault formula adjusted for body surface area.
RESULTS: Patients with impaired renal function (eGFR <60 ml min(-1) 1.73 m(-2)) had higher total cholesterol, triacylglycerol and apolipoprotein B, and lower HDL-cholesterol concentrations than patients with normal renal function (eGFR >90 ml min(-1) 1.73 m(-2)) or mildly impaired renal function (eGFR 60-90 ml min(-1) 1.73 m(-2)) (p < 0.001 for all associations). In type 1 diabetic patients without manifest renal disease, similar adverse lipid profiles could be observed in those who were overweight or obese and in those who had intermediate or poor glycaemic control or hypertension. In all the different patient groups 14 to 43% would have achieved the recommended target of <2.6 mmol/l for LDL-cholesterol. CONCLUSIONS/
INTERPRETATION: Multiple lipid abnormalities are not only present in type 1 diabetic patients with an abnormal AER, but also in those with impaired renal function. In patients without manifest renal disease, obesity, glycaemic control or hypertension were associated with an adverse lipid profile. A substantial number of patients studied would have exceeded the targets set by international guidelines, particularly the targets for LDL-cholesterol.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17994214     DOI: 10.1007/s00125-007-0858-y

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  38 in total

1.  Normoalbuminuria ensures no reduction of renal function in type 1 (insulin-dependent) diabetic patients.

Authors:  K W Hansen; M Mau Pedersen; C K Christensen; A Schmitz; J S Christiansen; C E Mogensen
Journal:  J Intern Med       Date:  1992-08       Impact factor: 8.989

2.  Standards of medical care in diabetes--2007.

Authors: 
Journal:  Diabetes Care       Date:  2007-01       Impact factor: 19.112

3.  Plasma lipoproteins from patients with poorly controlled diabetes mellitus and "in vitro" glycation of lipoproteins enhance the transfer rate of cholesteryl ester from HDL to apo-B-containing lipoproteins.

Authors:  M Passarelli; S Catanozi; E R Nakandakare; J C Rocha; R E Morton; A F Shimabukuro; E C Quintão
Journal:  Diabetologia       Date:  1997-09       Impact factor: 10.122

4.  Glomerular filtration rate, cardiorenal end points, and all-cause mortality in type 2 diabetic patients.

Authors:  Wing Yee So; Alice P S Kong; Ronald C W Ma; Risa Ozaki; Cheuk Chun Szeto; Norman N Chan; Vanessa Ng; Chung Shun Ho; Christopher W K Lam; Chun Chung Chow; Clive S Cockram; Juliana C N Chan; Peter C Y Tong
Journal:  Diabetes Care       Date:  2006-09       Impact factor: 19.112

5.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

6.  Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals.

Authors:  H C Gerstein; J F Mann; Q Yi; B Zinman; S F Dinneen; B Hoogwerf; J P Hallé; J Young; A Rashkow; C Joyce; S Nawaz; S Yusuf
Journal:  JAMA       Date:  2001-07-25       Impact factor: 56.272

7.  Serum lipids and the progression of nephropathy in type 1 diabetes.

Authors:  Merlin C Thomas; Milla Rosengård-Bärlund; Vashti Mills; Mats Rönnback; Stephen Thomas; Carol Forsblom; Mark E Cooper; Marja-Riitta Taskinen; Giancarlo Viberti; Per-Henrik Groop
Journal:  Diabetes Care       Date:  2006-02       Impact factor: 19.112

8.  Multiple lipoprotein abnormalities in type I diabetic patients with renal disease.

Authors:  P H Groop; T Elliott; A Ekstrand; A Franssila-Kallunki; R Friedman; G C Viberti; M R Taskinen
Journal:  Diabetes       Date:  1996-07       Impact factor: 9.461

9.  Glucosylation of low-density lipoproteins to an extent comparable to that seen in diabetes slows their catabolism.

Authors:  U P Steinbrecher; J L Witztum
Journal:  Diabetes       Date:  1984-02       Impact factor: 9.461

10.  Plasma lipid and coagulation factor concentrations in insulin dependent diabetics with microalbuminuria.

Authors:  S L Jones; C F Close; M B Mattock; R J Jarrett; H Keen; G C Viberti
Journal:  BMJ       Date:  1989-02-25
View more
  12 in total

1.  Tissue-specific metabolic reprogramming drives nutrient flux in diabetic complications.

Authors:  Kelli M Sas; Pradeep Kayampilly; Jaeman Byun; Viji Nair; Lucy M Hinder; Junguk Hur; Hongyu Zhang; Chengmao Lin; Nathan R Qi; George Michailidis; Per-Henrik Groop; Robert G Nelson; Manjula Darshi; Kumar Sharma; Jeffrey R Schelling; John R Sedor; Rodica Pop-Busui; Joel M Weinberg; Scott A Soleimanpour; Steven F Abcouwer; Thomas W Gardner; Charles F Burant; Eva L Feldman; Matthias Kretzler; Frank C Brosius; Subramaniam Pennathur
Journal:  JCI Insight       Date:  2016-09-22

2.  Lower levels of total HDL and HDL3 cholesterol are associated with albuminuria in normoalbuminuric Type 1 diabetic patients.

Authors:  T Bulum; B Kolaric; L Duvnjak
Journal:  J Endocrinol Invest       Date:  2013-02-12       Impact factor: 4.256

3.  Lipid abnormalities predict progression of renal disease in patients with type 1 diabetes.

Authors:  N Tolonen; C Forsblom; L Thorn; J Wadén; M Rosengård-Bärlund; M Saraheimo; M Feodoroff; V-P Mäkinen; D Gordin; M-R Taskinen; P-H Groop
Journal:  Diabetologia       Date:  2009-10-10       Impact factor: 10.122

4.  Risk of cardiovascular disease and total mortality in adults with type 1 diabetes: Scottish registry linkage study.

Authors:  Shona J Livingstone; Helen C Looker; Eleanor J Hothersall; Sarah H Wild; Robert S Lindsay; John Chalmers; Stephen Cleland; Graham P Leese; John McKnight; Andrew D Morris; Donald W M Pearson; Norman R Peden; John R Petrie; Sam Philip; Naveed Sattar; Frank Sullivan; Helen M Colhoun
Journal:  PLoS Med       Date:  2012-10-02       Impact factor: 11.069

5.  Bacterial endotoxin activity in human serum is associated with dyslipidemia, insulin resistance, obesity, and chronic inflammation.

Authors:  Mariann I Lassenius; Kirsi H Pietiläinen; Kati Kaartinen; Pirkko J Pussinen; Jaana Syrjänen; Carol Forsblom; Ilkka Pörsti; Aila Rissanen; Jaakko Kaprio; Jukka Mustonen; Per-Henrik Groop; Markku Lehto
Journal:  Diabetes Care       Date:  2011-06-02       Impact factor: 19.112

6.  Progression to microalbuminuria in patients with type 1 diabetes: a seven-year prospective study.

Authors:  Roberta A Cobas; Bráulio Santos; Pedro Cb da Silva; Ricardo Neves; Marilia B Gomes
Journal:  Diabetol Metab Syndr       Date:  2011-08-26       Impact factor: 3.320

7.  Serum lipopolysaccharide activity is associated with the progression of kidney disease in finnish patients with type 1 diabetes.

Authors:  Mariann Nymark; Pirkko J Pussinen; Anita M Tuomainen; Carol Forsblom; Per-Henrik Groop; Markku Lehto
Journal:  Diabetes Care       Date:  2009-06-05       Impact factor: 19.112

8.  Regional differences in clinical care among patients with type 1 diabetes in Brazil: Brazilian Type 1 Diabetes Study Group.

Authors:  Marília B Gomes; Roberta A Cobas; Alessandra S Matheus; Lucianne R Tannus; Carlos Antonio Negrato; Melanie Rodacki; Neuza Braga; Marilena M Cordeiro; Jorge L Luescher; Renata S Berardo; Marcia Nery; Maria do Carmo A Arruda-Marques; Luiz E Calliari; Renata M Noronha; Thais D Manna; Lenita Zajdenverg; Roberta Salvodelli; Fernanda G Penha; Milton C Foss; Maria C Foss-Freitas; Antonio C Pires; Fernando C Robles; Mariadefátimas Guedes; Sergio A Dib; Patricia Dualib; Saulo C Silva; Janice Sepulvida; Henriqueta G Almeida; Emerson Sampaio; Rosangela Rea; Ana Cristina R Faria; Balduino Tschiedel; Suzana Lavigne; Gustavo A Cardozo; Mirela J Azevedo; Luis Henrique Canani; Alessandra T Zucatti; Marisa Helena C Coral; Daniela Aline Pereira; Luiz Antonio Araujo; Monica Tolentino; Hermelinda C Pedrosa; Flaviane A Prado; Nelson Rassi; Leticia B Araujo; Reine Marie C Fonseca; Alexis D Guedes; Odelissa S Matos; Manuel Faria; Rossana Azulay; Adriana C Forti; Cristina Façanha; Ana Paula Montenegro; Renan Montenegro; Naira H Melo; Karla F Rezende; Alberto Ramos; João Sooares Felicio; Flavia M Santos; Deborah L Jezini; Marilena M Cordeiro
Journal:  Diabetol Metab Syndr       Date:  2012-10-29       Impact factor: 3.320

9.  Metabolic phenotypes, vascular complications, and premature deaths in a population of 4,197 patients with type 1 diabetes.

Authors:  Ville-Petteri Mäkinen; Carol Forsblom; Lena M Thorn; Johan Wadén; Daniel Gordin; Outi Heikkilä; Kustaa Hietala; Laura Kyllönen; Janne Kytö; Milla Rosengård-Bärlund; Markku Saraheimo; Nina Tolonen; Maija Parkkonen; Kimmo Kaski; Mika Ala-Korpela; Per-Henrik Groop
Journal:  Diabetes       Date:  2008-06-10       Impact factor: 9.461

10.  Association analysis of dyslipidemia-related genes in diabetic nephropathy.

Authors:  Gareth J McKay; David A Savage; Christopher C Patterson; Gareth Lewis; Amy Jayne McKnight; Alexander P Maxwell
Journal:  PLoS One       Date:  2013-03-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.